Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs has continued its on-market share buy-back program, repurchasing a total of 6,138,208 ordinary fully paid shares prior to the latest reporting date. The company bought back a further 250,000 shares on the previous trading day, underscoring ongoing capital management efforts aimed at reducing the share count and potentially enhancing shareholder value.
The latest filing is an update to the buy-back first notified in October 2025, with this announcement dated 23 March 2026. Regular daily notifications signal an active execution of the approved buy-back, which may influence trading liquidity and share price dynamics as the program progresses.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian pathology services provider operating in the healthcare diagnostics industry. The company focuses on medical laboratory testing and related diagnostic services, with its ordinary fully paid shares listed on the ASX under the code ACL.
Average Trading Volume: 745,122
Technical Sentiment Signal: Sell
Current Market Cap: A$369.2M
See more data about ACL stock on TipRanks’ Stock Analysis page.